Lifetree Clinical Research Expands Research Bed Capacity
Lifetree Clinical Research
has expanded its in-patient capacity from 60 to 75 beds in the early stage research unit at the 35,000-square-foot facility located at 700 E. 3838 S. in Salt Lake City, Utah. This expansion represents a greater than 100 percent increase in size since Lifetree Clinical Research was founded in 2003 at the same address as a 5,000-square-foot facility with eight beds.
The 25 percent increase in beds will allow Lifetree to conduct larger Phase I clinical research studies and support expansion into early stage research in new therapeutic areas such as experimental human models, Alzheimer’s disease, Hepatitis C, and broadened Neuropsychiatric capabilities. Despite an uncertain climate facing many of the nation’s contract research organizations, many of which reduced or eliminated bed capacity over the last four years, Lifetree continues to experience record growth and an expanding client base representing many of the nation’s leading pharmaceutical and biotech research and development companies.
Lifetree currently employs more than 100 Salt Lake City area residents in addition to other supporting personnel throughout the United States.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
